Preclinical studies indicated that blocking CD39 activity enhances the immune cell effect to several cancer cell lines and mouse models [20, 21], which may be an effective strategy to prevent the hydrolysis of immunogenic ATP and regulate immunosuppressive TME. This evidence concerns the gene ENTPD1 and cancer.